Founding price: Foundation is $69 for the first 250 buyers or until 31 Dec 2026, whichever comes first, then $79. Free creatine tub with Foundation, code FIRST100, one per customer, first 100 Foundation orders.$69 founding price. Free extra creatine tub, one per customer, first 100 Foundation orders.

Ratings

Grade change log

Every change to a published evidence grade: the date, the old and new grade, why, and the source. An independent grader with no stake in our products decides changes; we record them here.

Grades rate the published evidence for a molecule for a use. They do not rate our products, their quality or their testing.

  1. · Omega-3 ratings card (label only)

    Old: B New: BUnchanged

    Reason. Grade unchanged at B, scores unchanged at 19/25. On 20 Oct the card's main use was relabelled from "Maintaining healthy triglyceride levels" to "Omega-3 (EPA and DHA) status" without re-scoring, so the card and the separate EPA and DHA status claim row (A) looked like two grades for one claim. The card is now labelled as the overall omega-3 evidence profile, mostly triglyceride and heart trials, not the EPA and DHA status claim, with a note explaining why it sits next to the A claim row. No grade was re-scored in this change.

    Source: Skulas-Ray AC et al. Circulation. 2019;140(12):e673-e691 (cited on the omega-3 card). Decided by: Evidence team review.

  2. · Vitamin D3 ratings card (in the multivitamin)

    Old: B New: D

    Reason. Shown as B from 23 Oct, reverted. The card was rewritten around mechanisms (VDR calcium transport) and raised to B without the grader. Raising a low blood level is well supported, but the card grades the label uses, and the grader rated those D in 2025 data: vitamin D did not significantly reduce respiratory infections, and pooled trials found no bone benefit from vitamin D alone.

    Source: Jolliffe DA et al. Lancet Diabetes Endocrinol. 2025;13(4):307-320. Decided by: Evidence team review, restoring the letters the independent grader confirmed on 18 Oct 2026; the 23 Oct raises never had grader sign-off.

  3. · Daily multivitamin ratings card

    Old: B New: C

    Reason. Shown as B from 23 Oct, reverted. Raised to B on the COSMOS cognition results. Those are a few related trials in older adults with modest effects, which our key grades C (small or few human trials), and large trials found no effect on heart disease or death.

    Source: Gaziano JM et al. JAMA. 2012;308(18):1871-1880 (PHS II). Decided by: Evidence team review, restoring the letters the independent grader confirmed on 18 Oct 2026; the 23 Oct raises never had grader sign-off.

  4. · Magnesium glycinate ratings card

    Old: B New: C

    Reason. Shown as B from 23 Oct, reverted. Raised to B on absorption and enzyme-cofactor mechanisms plus one sleep trial. Mechanisms do not raise a grade under our key, and the sleep evidence for this form is one 2025 trial in 155 adults: grade C.

    Source: Schuster J et al. Nat Sci Sleep. 2025 (bisglycinate RCT). Decided by: Evidence team review, restoring the letters the independent grader confirmed on 18 Oct 2026; the 23 Oct raises never had grader sign-off.

  5. · Electrolytes ratings card

    Old: B New: C

    Reason. Shown as B from 23 Oct, reverted. Raised to B on endurance-race trials and position stands. Those cover heavy sweat in athletes, not the everyday adult use we grade, so the human evidence for our stated use stays C.

    Source: Sawka MN et al. Med Sci Sports Exerc. 2007;39(2):377-390. Decided by: Evidence team review, restoring the letters the independent grader confirmed on 18 Oct 2026; the 23 Oct raises never had grader sign-off.

  6. · L-theanine ratings card

    Old: B New: C

    Reason. Shown as B from 23 Oct, reverted. Raised to B on EEG alpha-wave and stress-marker findings. Those are surrogate and mechanistic measures from small, often industry-linked trials; pooled sleep results are small, so the grade stays C.

    Source: Bulman A et al. Sleep Med Rev. 2025 (meta-analysis). Decided by: Evidence team review, restoring the letters the independent grader confirmed on 18 Oct 2026; the 23 Oct raises never had grader sign-off.

  7. · Berberine ratings card

    Old: B New: C

    Reason. Shown as B from 23 Oct, reverted. Raised to B without new human data. The evidence on the card is unchanged, and the C from the grader stands.

    Source: Zhang Y et al. Nat Commun. 2020;11:5015 (PREMOTE). Decided by: Evidence team review, restoring the letters the independent grader confirmed on 18 Oct 2026; the 23 Oct raises never had grader sign-off.

  8. · Quercetin Phytosome ratings card and research summary

    Old: B New: C

    Reason. Shown as B from 23 Oct, reverted. Raised to B on cultured mast cell results and a bioavailability study. Cell studies are mechanistic and absorption is a surrogate; the largest community trial (about 1,000 adults) was null on CRP. C stands.

    Source: Mohammadi-Sartang M et al. Eur J Clin Nutr. 2017;71(9):1033-1039. Decided by: Evidence team review, restoring the letters the independent grader confirmed on 18 Oct 2026; the 23 Oct raises never had grader sign-off.

  9. · Keto BHB salts ratings card and research summary

    Old: B New: D

    Reason. Shown as B from 23 Oct, reverted. Raised to B by borrowing ketone ester and MCT results and lab mechanisms (NLRP3, HDAC). Salts raise blood BHB only modestly, and they were 2 of 38 studies (44 people) in the 2026 cognition review. D stands, and our own earlier posts said so.

    Source: Bonnechère B et al. Front Nutr. 2026 (meta-analysis). Decided by: Evidence team review, restoring the letters the independent grader confirmed on 18 Oct 2026; the 23 Oct raises never had grader sign-off.

  10. · Vitamin D3: bone health when your level is low (label use)

    Old: D New: DUnchanged

    Reason. Split from the combined row "bone health and normal immune function when your level is low" on the independent grader's recommendation. The bone row stays D, but its tag changes from Evidence against to Insufficient human evidence: pooled trials of vitamin D alone found no effect on fractures or falls, and exploratory or secondary analyses of two trials found bone density benefits in people starting at or below 30 nmol/L, but no fewer fractures have been shown in people who start low. That is not the same as evidence against. Severe deficiency can cause rickets and osteomalacia, which are diseases we do not grade.

    Source: Bolland MJ et al. Lancet Diabetes Endocrinol. 2018;6(11):847-858. Decided by: Independent grader (a separate reviewer with no stake in our products), changed 18 Oct 2026.

  11. · Vitamin D3: normal immune function when your level is low (label use, new row)

    Old: D New: DUnchanged

    Reason. New row, split from the combined row on the independent grader's recommendation, graded D, Insufficient human evidence. In the 2025 update of the infection trials, vitamin D did not significantly reduce respiratory infections in people starting below 25 nmol/L (odds ratio 0.98, 95% CI 0.80 to 1.20; 22 trials), and the review found no evidence that the effect differed by starting level. This is not proof of zero effect. These trials measured respiratory infections and do not establish a benefit, or its absence, for normal immune function as a whole. This replaces the Evidence against tag in the combined-row entry below.

    Source: Jolliffe DA et al. Lancet Diabetes Endocrinol. 2025;13(4):307-320. Decided by: Independent grader (a separate reviewer with no stake in our products), changed 18 Oct 2026.

  12. · Vitamin D3 ratings card: note on the grade and the 17/25 score

    Old: D New: DUnchanged

    Reason. Display change, no grade change. The card now explains why a D sits next to 17 of 25: the total combines an evidence profile, effect size and safety rather than measuring benefit alone, and effect size is 0 of 5 because a reliable benefit for the label uses is not established; this does not mean every trial found zero effect. Both label uses are now tagged Insufficient human evidence, replacing the Evidence against wording in the B to D card entry below. The card's use now notes the two claim rows, both D, and its value line no longer says yes if you test low.

    Source: Jolliffe DA et al. Lancet Diabetes Endocrinol. 2025;13(4):307-320. Decided by: Independent grader (a separate reviewer with no stake in our products), changed 18 Oct 2026.

  13. · Vitamin D and respiratory infections (health article)

    Old: B New: n/a

    Reason. Letter removed. Preventing respiratory infections is a disease use, which we do not grade, and a B next to "not proven to prevent" read like a support grade. The article now shows no letter and reports the 2025 update of the trials (odds ratio 0.94, 95% CI 0.88 to 1.00, not statistically significant). The separate vitamin D3 label-use grade is logged below.

    Source: Jolliffe DA et al. Lancet Diabetes Endocrinol. 2025;13(4):307-320. Decided by: Independent grader (a separate reviewer with no stake in our products), changed 18 Oct 2026.

  14. · Vitamin D3: bone and immune function when your level is low (label use)

    Old: B New: D

    Reason. Rechecked after the 2025 update of the vitamin D trials and changed from B (human trials) to D (evidence against). The B rested on fewer respiratory infections in people starting below 25 nmol/L in a 2017 pooled analysis. In the 2025 update, vitamin D did not significantly reduce infections in that group (odds ratio 0.98, 95% CI 0.80 to 1.20; 22 trials), and the review found no evidence that the effect differed by starting level. That review measured infections, not bone. For bone, severe deficiency can cause rickets and osteomalacia, which are diseases we do not grade. The combined row's D reflects the respiratory-infection evidence: direct trial evidence for a bone benefit specifically in people who start low is insufficient, which is not the same as evidence against it, and this review does not show whether correcting a low level helps bone.

    Source: Jolliffe DA et al. Lancet Diabetes Endocrinol. 2025;13(4):307-320. Decided by: Independent grader (a separate reviewer with no stake in our products), changed 18 Oct 2026.

  15. · Vitamin D3 ratings card (in the multivitamin)

    Old: B New: D

    Reason. Changed to match the independent grader's verdict on the same use, bone health and normal immune function when your level is low (B to D, evidence against). The card now states the vitamin D3 amount and the evidence limits; it does not claim a bone or immune benefit from the product.

    Source: Jolliffe DA et al. Lancet Diabetes Endocrinol. 2025;13(4):307-320. Decided by: Independent grader (a separate reviewer with no stake in our products), changed 18 Oct 2026.

  16. · Creatine: depression (disease use, not graded)

    Old: n/a New: n/aUnchanged

    Reason. Display change, no grade change. Depression is a disease, so we never grade it. The row is no longer shown on the creatine science page, which sits next to the product we sell; it stays on the full claims list with the same text.

    Source: Everstack: all claims we track. Decided by: Evidence team review.

  17. · NR ratings card: raising blood NAD+

    Old: C New: B

    Reason. Changed to match the independent grader's verdict on the same use: several independent trials consistently show NR raises blood NAD+. Blood NAD+ is a marker, not a health outcome, and it has not been shown to slow aging or improve function; that row stays D. The NR add-on label grade (C) covers cellular NAD+, which the trials did not show in muscle, and is unchanged.

    Source: Elhassan YS et al. Cell Rep. 2019;28(7):1717-1728. Decided by: Independent grader (a separate reviewer with no stake in our products), changed 18 Oct 2026.

  18. · Multivitamin: filling common nutrient gaps (label use)

    Old: None New: C

    Reason. New per-claim row, confirmed. A multivitamin raises intake, but trials of nutrient status in well-fed adults are few, and heart and cancer trials do not answer this claim.

    Source: NIH Office of Dietary Supplements: Multivitamin/mineral supplements fact sheet. Decided by: Independent grader (a separate reviewer with no stake in our products), confirmed 18 Oct 2026.

  19. · Multivitamin: slowing memory decline in older adults

    Old: None New: C

    Reason. New per-claim row, confirmed. The memory signal comes from three analyses of one trial, with the product donated by its maker, and no independent trial has repeated it.

    Source: Vyas CM et al. Am J Clin Nutr. 2024;119(3):692-701. Decided by: Independent grader (a separate reviewer with no stake in our products), confirmed 18 Oct 2026.

  20. · Multivitamin: living longer

    Old: None New: D

    Reason. New per-claim row, confirmed. An 11-year trial in 14,641 men and cohorts of about 390,000 adults found no lower death rates.

    Source: Loftfield E et al. JAMA Netw Open. 2024;7(6):e2418729. Decided by: Independent grader (a separate reviewer with no stake in our products), confirmed 18 Oct 2026.

  21. · Vitamin D3: bone and immune function when your level is low (label use)

    Old: None New: B

    Reason. New per-claim row, confirmed. Benefits cluster in people who start low. Not an A because much of the bone evidence is vitamin D with calcium, the infection effect is modest, and people with normal levels do not clearly benefit.

    Source: Martineau AR et al. BMJ. 2017;356:i6583. Decided by: Independent grader (a separate reviewer with no stake in our products), confirmed 18 Oct 2026.

  22. · Berberine: lower blood sugar

    Old: None New: B

    Reason. New per-claim row. We proposed C; the grader raised it to B because two meta-analyses and a 20-centre trial agree. Not an A because most trials are short, done in China and in people who already had high blood sugar or diabetes. Our overall berberine rating (C, for healthy glucose metabolism in people without diabetes) is unchanged.

    Source: Zhao JV et al. J Nutr. 2023;153(10):2939-2950. Decided by: Independent grader (a separate reviewer with no stake in our products), changed 18 Oct 2026.

  23. · NR: raising NAD+ in the blood

    Old: None New: B

    Reason. New per-claim row. We proposed C; the grader raised it to B because several independent trials consistently show NR raises blood NAD+. Blood NAD+ is still a marker, and muscle NAD+ did not rise in one trial, so not an A.

    Source: Elhassan YS et al. Cell Rep. 2019;28(7):1717-1728. Decided by: Independent grader (a separate reviewer with no stake in our products), changed 18 Oct 2026.

  24. · NR: slowing aging or living longer

    Old: None New: D

    Reason. New per-claim row, confirmed. No trial has measured lifespan or a validated aging outcome, and trials on muscle, cognition, blood pressure and fatigue are mostly null.

    Source: Brakedal B et al. JAMA. Published online Oct 2026 (NOPARK). Decided by: Independent grader (a separate reviewer with no stake in our products), confirmed 18 Oct 2026.

  25. · L-theanine: feeling calm and sleeping better

    Old: None New: C

    Reason. New per-claim row, confirmed. Reviews report a small benefit, but many sleep trials used blends, the theanine-only sleep trials were not pooled, and several studies have industry ties.

    Source: Bulman A et al. Sleep Med Rev. 2025;81:102076. Decided by: Independent grader (a separate reviewer with no stake in our products), confirmed 18 Oct 2026.

  26. · Apigenin: falling asleep and staying asleep

    Old: None New: D

    Reason. New per-claim row. Grade D confirmed; the grader changed the tag from Mixed to Preclinical only, because no trial has tested pure apigenin and chamomile extracts do not count for the single ingredient.

    Source: Zick SM et al. BMC Complement Altern Med. 2011;11:78. Decided by: Independent grader (a separate reviewer with no stake in our products), changed 18 Oct 2026.

  27. · Apigenin: lowering estrogen

    Old: None New: D

    Reason. New per-claim row, confirmed. Aromatase inhibition is a 1984 lab result, and no human trial has measured estrogen after apigenin.

    Source: Kellis JT, Vickery LE. Science. 1984;225(4666):1032-1034. Decided by: Independent grader (a separate reviewer with no stake in our products), confirmed 18 Oct 2026.

  28. · Magnesium L-threonate: sleep and memory

    Old: None New: C

    Reason. New per-claim row, confirmed. One small company-funded trial on cognition and one short trial on sleep, with strong placebo effects and no independent replication; a multi-ingredient formula trial does not count.

    Source: Hausenblas HA et al. Sleep Med X. 2024;8:100121. Decided by: Independent grader (a separate reviewer with no stake in our products), confirmed 18 Oct 2026.

  29. · Protein: more muscle with resistance training

    Old: None New: A

    Reason. New per-claim row, confirmed. A meta-analysis of 49 randomized trials found a small, consistent gain in muscle and strength; total daily protein matters more than the source.

    Source: Morton RW et al. Br J Sports Med. 2018;52:376-384. Decided by: Independent grader (a separate reviewer with no stake in our products), confirmed 18 Oct 2026.

  30. · Glycine: lifespan in mice

    Old: None New: D

    Reason. New per-claim row. Mouse and rat data only (Miller 2019; Brind 2011 abstract); no human trial has measured lifespan, so the grade is capped at D.

    Source: Miller RA et al. Aging Cell. 2019;18(3):e12953. Decided by: Independent grader (a separate reviewer with no stake in our products), confirmed 18 Oct 2026.

  31. · Glycine: healthy aging markers with GlyNAC

    Old: None New: D

    Reason. New per-claim row. Small trials from one group (Kumar 2023) and an independent null trial (Lizzo 2022); GlyNAC is a combination, so it does not count for glycine alone.

    Source: Lizzo G et al. Front Aging. 2022. Decided by: Independent grader (a separate reviewer with no stake in our products), confirmed 18 Oct 2026.

  32. · Glycine: collagen for skin or joints

    Old: None New: D

    Reason. New per-claim row. A modeling argument only; no human trial of glycine alone on skin or joints.

    Source: Meléndez-Hevia E et al. J Biosci. 2009. Decided by: Independent grader (a separate reviewer with no stake in our products), confirmed 18 Oct 2026.

  33. · Glycine: sleep quality (label use)

    Old: C New: CUnchanged

    Reason. Grade unchanged. The headline grade is now scoped to the label use ("Sleep quality: C") instead of standing for glycine as a whole.

    Source: Soh J et al. Geroscience. 2024;46(1):219-239. Decided by: Independent grader (a separate reviewer with no stake in our products), confirmed 18 Oct 2026.

  34. · GlyNAC article

    Old: D New: DUnchanged

    Reason. Grade unchanged; reason corrected. The article had said no independent replication existed. It now cites the independent Lizzo 2022 trial, which did not raise glutathione versus placebo.

    Source: Lizzo G et al. Front Aging. 2022. Decided by: Independent grader (a separate reviewer with no stake in our products), confirmed 18 Oct 2026.

  35. · Omega-3: a higher Omega-3 Index and longer life

    Old: C New: D

    Reason. Changed by the independent grader. No randomized trial has tested whether a higher index lengthens life, and large EPA and DHA trials found no reduction in death; cohort numbers do not establish the claim. Our Omega-3 Index summary keeps grade C for the index as a marker of intake.

    Source: Manson JE et al. N Engl J Med. 2019;380(1):23-32 (VITAL). Decided by: Independent grader (a separate reviewer with no stake in our products), changed 18 Oct 2026.

  36. · Creatine: strength and lean mass (label use)

    Old: None New: A

    Reason. New per-claim row, confirmed. Several meta-analyses of randomized trials agree, including 22 trials in older adults.

    Source: Chilibeck PD et al. Open Access J Sports Med. 2017;8:213-226. Decided by: Independent grader (a separate reviewer with no stake in our products), confirmed 18 Oct 2026.

  37. · Creatine: memory and thinking

    Old: None New: C

    Reason. New per-claim row, confirmed. Meta-analyses were criticized for double counting and EFSA found no established effect; positive signals are small, often high-dose and in subgroups. Depression is listed as a disease use and not graded.

    Source: Everstack summary: creatine and the brain. Decided by: Independent grader (a separate reviewer with no stake in our products), confirmed 18 Oct 2026.

  38. · Magnesium glycinate: relaxation and sleep quality (label use)

    Old: None New: C

    Reason. New per-claim row, confirmed. One bisglycinate trial found a very small, borderline effect on one sleep score; the meta-analysis of other forms is low certainty.

    Source: Schuster J et al. Nat Sci Sleep. 2025;17:2027-2040. Decided by: Independent grader (a separate reviewer with no stake in our products), confirmed 18 Oct 2026.

  39. · Omega-3: healthy triglyceride levels (label use)

    Old: None New: B

    Reason. New per-claim row, confirmed. Many randomized trials agree, but the consistent 20 to 30% drop is at about 4 g a day, far above a 600 mg serving, so not an A.

    Source: Skulas-Ray AC et al. Circulation. 2019;140(12):e673-e691. Decided by: Independent grader (a separate reviewer with no stake in our products), confirmed 18 Oct 2026.

  40. · Berberine (Metabolic add-on)

    Old: B New: C

    Reason. Lowered to match our research review: the glucose trials are small and of low quality.

    Source: Everstack summary: berberine and glucose metabolism. Decided by: Evidence team review.

What people are hearing · How we grade